Use of radioactive phosphorus in haematology

Blood Reviews

Volumn 11, Issue 3, 1997, Pages 146-153

  Roberts, B E ^a   Smith, A H ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; PHOSPHORUS 32; TRACER;

BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG ABSORPTION; DRUG HALF LIFE; HEMATOLOGY; HUMAN; LEUKEMOGENESIS; MYELOMA; MYELOPROLIFERATIVE DISORDER; NUCLEAR MEDICINE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW;

EID: 0030685062     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90009-6     Document Type: Article

References (27)

1. Lawrence JH. Some tracer and therapeutic studies with articial radioactivity. Br J Radiol 1948; 21: 531.
2. Silberstein EB. Radionuclide therapy of hematologic disorders. Sem Nucl Med 1979; 9: 100.
3. Annals of the International Committee on Radiation Protection Publication 62, Vol 22, No 3. Radiological Protection in Biomedical Research - Addendum 1 to ICRP Publication 53, p 25. Oxford: Pergamon Press 1991.
4. International Committee on Radiation Protection Publication 53, Vol 18 No 1-4. Radiation Dose to Patients from Radiopharmaceticals p 15. Oxford: Pergamon Press, 1987.
5. 32P. Br J Radiol 1976; 49: 133.
6. Seltzer RA, Kereiakes JG, Saenger EL. Pediatric radiation exposures. N Engl J Med 1964; 271: 84.
7. 32P. Am J Roetgenol 1952; 67: 28.
8. International Committee on Radiological Protection Publication 17. Protection of the patient in radionuclide investigations, p 64, 1971.
9. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI. Wasserman LR. Therapeutic recommendations in polycythaemia vera based on polycythaemia vera study group protocols. Sem Haematol 1986; 23: 132.
10. Vaquez MH. Sur un form spéciale de cyanose s'accompagnant d'hyperglobulie excessive et persistante. CR Soc Biol 1892; 44: 384.
11. Osier W. Chronic cyanosis with polycythaemia and enlarged spleen: a new clinical entity. Am J Med Sci 1903; 126: 187.
12. Osler W. Erythraemia (polycythaemia with cyanosis, maladie de Vaquez). Lancet 1908; 1: 143.
13. Lawrence JH, Berlin NI, Huff RL. The nature and treatment of polycythaemia. Medicine 1953; 32: 323.
14. Gaisbock F. Die Polycythaemia. Ergeb inn Med u Kinderheilk 1922; 21: 234.
15. Videback A. Polycythaemia vera: course and prognosis. Acta Med Scand 1950; 138: 179.
16. Lawrence JH, Dobson RL, Low-Beer BVA, Brown BR. Chronic myelogenous leukaemia. A study of 129 cases in which treatment was with radioactive phosphorus. JAMA 1948; 136: 672.
17. Lawrence JH, Low-Beer BVA, Carpender JWJ. Chronic lymphatic leukaemia. A study of 100 patients treated with radioactive phosphorus. JAMA 1949; 140: 585.
18. 89. Ann Int Med 1950; 33: 41.
19. Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand 1962; 172: 513.
20. Lawrence JH, Winchell HS, Donald WG. Leukaemia in polycythaemia vera: relationship to splenic myeloid metaplasia and therapeutic radiation dose. Ann Intern Med 1969; 70: 763.
21. Heller EL, Lewisohn MG, Palin WE. Aleukaemic myelosis. Am J Pathol 1947; 23: 327.
22. Wasserman LR, Polycythaemia Vera Study Group. A historical perspective. Sem Haematol 1986; 23: 183.
23. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Long-term management of polycythaemia vera with hydroxyurea: a progress report. Sem Haematol 1986; 23: 167.
24. Tatarsky I, Sharon R Management of polycythaemia vera with hydroxyurea. Sem Haematol 1997; 34: 24.
25. Najean Y, Dresch C, Rain JR. The very long term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol 1994; 86: 233.
26. 32P between 1969 and 1981. Sem Haematol 1997; 34: 6.
27. Nand S, Messmore H, Fischer SG et al. Leukaemic transformation in PV Am J Haematol 1990; 34: 32.